Welcome to our dedicated page for Red Light Hollan news (Ticker: TRUFF), a resource for investors and traders seeking the latest updates and insights on Red Light Hollan stock.
Red Light Holland Corp (TRUFF) generates news across functional mushrooms, psilocybin truffles, retail distribution, research collaborations, and treasury strategy. The company describes itself as an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal recreational market within the Netherlands, in compliance with all applicable laws.
News updates frequently cover financial and operational results, where Red Light Holland reports on cash balances, revenue trends, and performance of its various business units. These releases often include commentary on management’s priorities, such as streamlining operations, evaluating non-core assets, and exploring mergers and acquisitions that could support its mushroom and psilocybin-related activities.
Another major news theme is research and development in psilocybin. Articles detail the company’s partnership with Irvine Labs Inc., an FDA-compliant and DEA-registered facility in California, including shipments of naturally occurring psilocybin truffles from the Netherlands under United States Controlled Substances import permits, potency testing, Certificates of Analysis, and work on proprietary dehydration and packaging processes. Updates also highlight collaborations like the Psychedelic Genome Project at Arizona State University and the appointment of a scientific advisor in psychedelic neuroscience.
Red Light Holland news also follows consumer and retail milestones, such as Happy Caps Mushroom Farm’s expansion into Safeway stores in Oregon and Washington State, seasonal retail programs, and the launch of functional mushroom gummies on Amazon and in Canadian supermarkets. Additional coverage addresses the company’s Bitcoin balance sheet strategy, including purchases of Bitcoin exchange-traded fund shares and work with cryptocurrency advisors.
Investors and observers can use the TRUFF news feed to review earnings announcements, R&D progress, retail distribution developments, and strategic updates as the company reports them.
Red Light Holland (OTCQB: TRUFF), a company focused on functional mushrooms and psilocybin truffles, has selected Arch Public Inc. as its partner for executing Bitcoin purchases, following advice from Lead Cryptocurrency Advisor Scott Melker. This decision aligns with the company's recently announced Bitcoin balance sheet strategy from July 15, 2025.
The company is implementing a C$2 million allocation to Bitcoin and related assets, with strategic investments of up to C$250,000 per tranche. Red Light Holland has already invested C$210,000 in a Bitcoin ETF on June 23, 2025. Arch Public's algorithmic trading platform will help optimize Bitcoin entry points and enhance treasury diversification through automated, emotion-free trading strategies.
Red Light Holland (OTCQB: TRUFF), a producer of functional mushrooms and psilocybin truffles, has announced a significant Bitcoin Balance Sheet Strategy with a planned allocation of up to C$2 million to Bitcoin and related assets. The company has already invested an initial C$210,000 in a Bitcoin ETF on June 23, 2025.
The company has appointed cryptocurrency expert Scott Melker as Senior Advisor and Crypto Czar, effective July 14, 2025. Melker, known as "The Wolf of All Streets" with over 1 million followers on X, will receive 3,333,333 restricted stock units vesting over 12 months. This strategic move follows the company's experience of being debanked by a Tier 1 bank, leading them to embrace Bitcoin as a store of value.
Red Light Holland (OTCQB: TRUFF) has achieved a significant milestone by completing the first-ever global shipment of naturally occurring psilocybin from its Netherlands facility to Irvine Labs, an FDA-compliant and DEA-registered facility in California. The shipment was made possible through a USA Controlled Substances import permit.
The partnership aims to develop commercialized and standardized psilocybin products for emerging markets and government-funded programs within the United States. Irvine Labs will conduct potency testing and implement advanced shelf life extension protocols on the received materials, leveraging their proprietary preservation technology to maintain product integrity throughout the supply chain.
The company's 2025 DEA quota allocation allows for scaling of R&D processes, with larger shipments being planned for future development.
Red Light Holland (OTCQB: TRUFF), a producer of functional mushrooms and psilocybin truffles, has appointed renowned psychedelic researcher Dr. Robin Carhart-Harris as Scientific Advisor. Dr. Carhart-Harris will provide strategic guidance on psilocybin research and assist with academic and regulatory collaborations.
The company highlighted several ongoing initiatives, including: partnerships with Dr. David Nutt and Drug Science for microdosing app data analysis, development of natural microdosing capsules with CCREST Labs, collaboration with Irvine Labs for shelf-life studies, distribution agreement with Allu Therapeutics for Australia/New Zealand markets, and an upcoming research collaboration with Arizona State University for psychedelic genome research.
Red Light Holland (TRUFF) has announced that its subsidiary Happy Caps has successfully restocked its Mushroom Home Grow Kits in Costco Canada stores nationwide. Following Costco's Informal Projection Letter, the company delivered 20,160 units of their new 2kg "Mega Block" Mushroom Home Grow Kits, featuring Shiitake, Lion's Mane, and Oyster varieties. The kits are now available in select Costco Canada locations coast to coast, just in time for Victoria Day weekend.
Happy Caps products now have seasonal presence in over 430 retail stores across North America, marking significant expansion for the brand's functional mushrooms and home grow kits business.
Red Light Holland's subsidiary Happy Caps has launched presales of Health Canada approved Functional Mushroom Gummies through their website. The sugar-free gummies, containing Shiitake and Lion's Mane mushrooms, received Natural Product Number (NPN #80137179) certification, confirming their safety and effectiveness.
The gummies offer several Health Canada recognized benefits, including being a source of fungal polysaccharides with immunomodulating properties and antioxidants. Happy Caps is offering a limited-time 25% discount for early adopters, with shipping scheduled for June. The company is pursuing both direct-to-consumer and B2B sales channels to expand market reach across North America.
Red Light Holland (OTCQB: TRUFF) has announced that its subsidiary Happy Caps Mushroom Farms has launched its Mushroom Home Grow Kits in 66 Safeway stores across Oregon and Washington. This marks Happy Caps' first U.S. retail rollout, featuring three varieties: Shiitake, Lion's Mane, and Oyster mushrooms.
Each participating Safeway store has received 36 grow kits (12 units of each variety) along with branded floor displays. The products feature U.S.-specific packaging with 'Made in the USA' and 'Certified Organic' labels. Happy Caps is collaborating with Trailbridge Farms in Oregon for local production and restocking.
This expansion builds upon Happy Caps' existing presence in over 430 retail stores across North America. The company is working with Albertsons Companies, which operates more than 2,200 stores throughout the United States.
Red Light Holland (TRUFF) announces a significant milestone as its partner Irvine Labs, an FDA-compliant and DEA-registered facility in California, has received its 2025 psilocybin DEA quotas including an import quota.
The companies will now proceed with the import permit application process to enable shipping of natural psilocybin products from Red Light Holland's Netherlands farm to Irvine's facilities. Once materials arrive, Irvine Labs will test proprietary dehydration and packaging solutions aimed at extending the shelf life of naturally derived psilocybin microdosing capsules.
Irvine Labs, licensed for prescription and OTC drug manufacturing by the California Department of Public Health, holds DEA Schedule 1 authorization for various substances including psilocybin. The partnership aims to develop commercialized products for export to emerging markets and use in government-funded pilot programs and clinical trials within the United States.